Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium.
PMID: 28760216 ·
J, o, n, a, t, h, a, n, , H, , S, e, l, t, z, e, r, ;, , T, e, d, , H, e, i, s, e, ;, , P, e, t, e, r, , C, a, r, s, o, n, ;, , D, a, n, i, e, l, , C, a, n, o, s, ;, , J, o, , C, a, r, o, l, , H, i, a, t, t, ;, , P, a, s, c, a, l, , V, r, a, n, c, k, x, ;, , T, h, o, m, a, s, , C, h, r, i, s, t, e, n, ;, , D, o, n, a, l, d, , E, , C, u, t, l, i, p
광고
초록
This white paper provides a summary of presentations, discussions and conclusions of a Thinktank entitled "The Role of Endpoint Adjudication in Medical Device Clinical Trials". The think tank was cosponsored by the Cardiac Safety Research Committee, MDEpiNet and the US Food and Drug Administration (FDA) and was convened at the FDA's White Oak headquarters on March 11, 2016. Attention was focused on tailoring best practices for evaluation of endpoints in medical device clinical trials, practical
광고
공식 출처
PubMed에서 보기 →데이터는 PubMed / NCBI에서 제공됩니다. 전문과 최신 정보는 반드시 공식 기록을 확인하세요.